Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV exhibits a strong financial outlook driven by a significant increase in management confidence regarding the efficacy of AMT-130 for Huntington's disease, supported by robust data and broad scientific endorsement. While SG&A expenses have risen to $19.4 million from $11.6 million year-over-year, the absence of new regulatory concerns surrounding manufacturing and safety enhances the risk-benefit profile of its therapies. Furthermore, the positive Independent Data Monitoring Committee (IDMC) review on AMT-260 for mesial temporal lobe epilepsy signifies progress in the company’s clinical pipeline, emphasizing potential for future revenue generation as it expands its therapeutic offerings.

Bears say

UniQure NV faces a negative outlook primarily due to the prospect of significant delays in its Biologics License Application (BLA) submission for AMT-130, as management has withdrawn prior guidance for a submission in the first quarter of 2026. The company's lack of commercially available products and ongoing financial losses since its inception heighten the financial risks associated with its clinical development stage. Additionally, increased market competition from existing and emerging therapies for similar indications poses a further threat to uniQure’s potential market penetration and pricing power.

uniQure (QURE) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 10 analysts, uniQure (QURE) has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.